

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/M8456EEC7E19EN.html>

Date: June 2022

Pages: 81

Price: US\$ 3,500.00 (Single User License)

ID: M8456EEC7E19EN

Abstracts

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Myc (c-Myc) protein encoded by Myc gene, a regulator gene that code for a transcription factor. The protein plays a role in cell cycle progression, apoptosis and cellular transformation. Myc protein is a transcription factor that activates expression of many genes through binding enhancer box sequences and recruiting histone acetyltransferases. It also acts as a transcriptional repressor. By binding Miz-1 transcription factor and displacing the p300 co-activator, it inhibits expression of Miz-1 target genes. In addition, myc has a direct role in the control of DNA replication. Myc is a proto-oncogene and it often upregulates in many types of cancers. Myc over expression stimulates gene amplification presumably through DNA over-replication.

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) pipeline Target constitutes close to 31 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 12 and 12 respectively. Similarly, the

universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Unspecified Cancer, Solid Tumor, Hematological Tumor, Lymphoma, Breast Cancer, Burkitt Lymphoma, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Multiple Myeloma (Kahler Disease), Non-Small Cell Lung Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), Blood Cancer, Colon Cancer, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Leukemia, Lung Cancer, Medulloblastoma, Metastatic Brain Tumor, Neuroblastoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Retinoblastoma, Small-Cell Lung Cancer, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) and Triple-Negative Breast Cancer (TNBC).

The latest report Myc Proto Oncogene Protein – Drugs In Development, 2022, outlays comprehensive information on the Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC)

The report reviews Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics under development by companies and universities/research institutes based on

information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics and enlists all their major and minor projects

The report assesses Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Overview

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Companies Involved in Therapeutics Development

Anima Biotech Inc

Arrakis Therapeutics Inc

Arvinas Inc

Biogenera SpA

Ceptur Therapeutics Inc

Cotherra Bioscience Pty Ltd

Erasca Inc

Escend Pharmaceuticals Inc

Gibson Oncology LLC

Kintor Pharmaceutical Ltd

Kronos Bio Inc

MecRx Pty Ltd

Omega Therapeutics Inc

OncoViRx LLC

Origenis GmbH

Peptomyc SL

PYC Therapeutics Ltd

Recursion Pharmaceuticals Inc

Sapience Therapeutics Inc

SyntheX Inc

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Drug Profiles

Amy-22 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BGA-003 – Drug Profile

Product Description

Mechanism Of Action

Drugs to Inhibit MYC for Breast Cancer – Drug Profile

Product Description

Mechanism Of Action

ERAS-11 – Drug Profile

Product Description

Mechanism Of Action

ES-4000 – Drug Profile

Product Description

Mechanism Of Action

GT-19077 – Drug Profile

Product Description

Mechanism Of Action

History of Events

GT-19630 – Drug Profile

Product Description

Mechanism Of Action

Myc – Drug Profile

Product Description

Mechanism Of Action

History of Events

MYC – Drug Profile

Product Description

Mechanism Of Action

MYC (Oncology) – Drug Profile

Product Description

Mechanism Of Action

History of Events

NOV-1701 – Drug Profile

Product Description

Mechanism Of Action

Oligonucleotides to Inhibit MYC for Hepatocellular Carcinoma and Non Small Cell Lung Cancer – Drug Profile

Product Description

Mechanism Of Action

OMO-101 – Drug Profile

Product Description

Mechanism Of Action

OMO-103 – Drug Profile

Product Description

Mechanism Of Action

History of Events

OTX-2002 – Drug Profile

Product Description

Mechanism Of Action

History of Events

PC-002p – Drug Profile

Product Description

Mechanism Of Action

REC-0162977 – Drug Profile

Product Description

Mechanism Of Action

REC-841 – Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Target c-Myc for Multiple Myeloma – Drug Profile

Product Description

Mechanism Of Action

Small Molecules 3 to Inhibit C-Myc for Unspecified Cancer – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit c-Myc for Oncology – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit C-Myc for Oncology – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit C-Myc for Unspecified Cancer – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit cMYC and PTEN for Unspecified Cancers – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit cMyc for Oncology – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit MYC and NFKB for Lymphomas and Leukemias – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit MYC and TOP1 for Oncology – Drug Profile

Product Description

Mechanism Of Action

History of Events

STX-300 – Drug Profile

Product Description

Mechanism Of Action

Synthetic Peptide to Inhibit C-Myc for Oncology – Drug Profile

Product Description

Mechanism Of Action

History of Events

Synthetic Peptide to Inhibit cMyc for Hematological Tumor and Solid Tumor – Drug Profile

Product Description

Mechanism Of Action

Target 1 (PPI Modulator) – Drug Profile

Product Description

Mechanism Of Action

History of Events

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Dormant Products

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Discontinued Products

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Product Development Milestones

Featured News & Press Releases

Jun 23, 2022: Omega Therapeutics to present new preclinical data for the first epigenomic controller, OTX-2002, for hepatocellular carcinoma at the European Society of Medical Oncology's 2022 World Congress on Gastrointestinal Cancer

Jun 15, 2022: Omega Therapeutics announces submission of Investigational New Drug application for OTX-2002, an Omega Epigenomic Controller, for MYC driven hepatocellular carcinoma

Apr 08, 2022: Omega Therapeutics presents preclinical data on OTX-2002, first-in-class epigenomic controller, as potential treatment for hepatocellular carcinoma at the AACR Annual Meeting 2022

Mar 08, 2022: Omega Therapeutics to present preclinical data for OTX-2002 at the American Association for Cancer Research Annual Meeting 2022

May 06, 2021: Peptomyc SL announces treatment of first patient with its lead compound OMO-103 in a phase I/II clinical trial

Mar 17, 2021: Omomyc, a drug developed in Vall d'Hebron, is coming to the clinical trial

Jul 30, 2020: VHIO and home-grown spin-off Peptomyc S.L receive further funding to bring Omomyc closer to the clinic

Jun 22, 2020: Pioneer Pharmaceuticals released the latest research results of c-Myc inhibitors at the AACR annual meeting

Apr 01, 2019: First published demonstration of the success of Myc inhibition by Omomyc mini-protein hits Science Translational Medicine and the news

Mar 26, 2019: Preclinical validation of new cancer inhibitor from EIT Health-supported Peptomyc

Mar 14, 2019: A new approach to drugging a difficult cancer target

Dec 09, 2015: Combination therapy escalates potency of Phylogica peptides against MYC-driven cancer

Nov 16, 2015: Phylogica exceeds gold - standard for treatment of MYC - driven cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Anima Biotech Inc, 2022

Pipeline by Arrakis Therapeutics Inc, 2022

Pipeline by Arvinas Inc, 2022

Pipeline by Biogen SpA, 2022

Pipeline by Ceptur Therapeutics Inc, 2022

Pipeline by Cothera Bioscience Pty Ltd, 2022

Pipeline by Erasca Inc, 2022

Pipeline by Escend Pharmaceuticals Inc, 2022

Pipeline by Gibson Oncology LLC, 2022

Pipeline by Kintor Pharmaceutical Ltd, 2022

Pipeline by Kronos Bio Inc, 2022

Pipeline by MecRx Pty Ltd, 2022

Pipeline by Omega Therapeutics Inc, 2022

Pipeline by OncoViRx LLC, 2022

Pipeline by Origenis GmbH, 2022

Pipeline by Peptomyc SL, 2022

Pipeline by PYC Therapeutics Ltd, 2022

Pipeline by Recursion Pharmaceuticals Inc, 2022

Pipeline by Sapience Therapeutics Inc, 2022

Pipeline by SyntheX Inc, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/M8456EEC7E19EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M8456EEC7E19EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970